FindTrial
Sign In

Clinical pathological characteristics and clinical efficacy of rare drive gene mutations in NSCLC in China, multi-center, observational and real-world research

Clinical pathological characteristics and clinical efficacy of rare drive gene mutations in NSCLC in China, multi-center, observational and real-world research

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047598
Enrollment
Unknown
Registered
2021-06-20
Start date
2021-06-21
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer (NSCLC)

Interventions

case series:Null

Sponsors

Shanghai Pulmonary Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, no gender limit; 2. Diagnosed with NSCLC by pathology or cytology; 3. Patients with positive test results for any gene mutation of EGFR-Ex20ins, ALK, ROS1, RET, HER2, MET, KRAS, NRAS, BRAF, PIK3CA; 4. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with tumors from other systemic origins; 2. The investigator's judgment may affect the conduct of clinical research and the judgment of research results.

Design outcomes

Primary

MeasureTime frame
Frequency of rare driver gene mutations;—

Secondary

MeasureTime frame
Objective response rate;Progression-free survival;Overall survival;—

Countries

China

Contacts

Public ContactZhou Caicun

Shanghai Pulmonary Hospital

caicunzhoudr@126.com+86 21 65115006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026